Phathom Pharmaceuticals (Phathom Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Apr. 26, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Phathom Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-04-26), Phathom Pharmaceuticals's share price is $9.18. Phathom Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.72. Hence, Phathom Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Phathom Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

PHAT's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.725
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Phathom Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.76. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.72.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -8.50% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -61.10% per year.

During the past 6 years, Phathom Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was -5.30% per year. The lowest was -223.10% per year. And the median was -8.50% per year.

Phathom Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Phathom Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phathom Pharmaceuticals Price-to-Operating-Cash-Flow Chart

Phathom Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Phathom Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Phathom Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Phathom Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phathom Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Phathom Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Phathom Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

Phathom Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	9.18	/	-2.721
	=

Phathom Pharmaceuticals's Share Price of today is $9.18.
Phathom Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.72.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Phathom Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Phathom Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Phathom Pharmaceuticals (Phathom Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phathom Pharmaceuticals Inc (NAS:PHAT) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932

Website

https://www.phathompharma.com

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Executives

Molly Henderson	officer: CFO and CBO	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Asit Parikh	director	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Azmi Nabulsi	officer: Chief Operating Officer	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
David A Socks	director, officer: President, CEO, Treas. & Sec.	C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Anthony J. Guzzo	officer: VP, Chief Accounting Officer	C/O US SHIPPING PARTNERS L.P., 399 THORNALL STREET, EDISON NJ 08837
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Todd P. Branning	officer: Chief Financial Officer	C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Mark Stenhouse	director	5505 ENDEAVOR LANE, MADISON WI 53719
Michael F Cola	director	435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Frazier Life Sciences Ix, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Jonathan S. Edwards	director	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116